2Bergman AM,Pinedo HM,Tallanidis 1,et al. Increased sensitivity to gemcitabine of P - glycoprotein and multi - drug resistance - associated protein -overexpressing human cancer cell lines. Br[ J ]. Cancer,2003,88(12) : 1963.
3van der Pol MA,Broxterman HJ,Paler JM,et at. Function of the ABC transporters, P - gtycoprotein, muhidrug resistance protein and breast cancer resistance protein,inminimal residual disease in acute myeloid leukemia [ J ]. Haematologica, 2003,88 (2) :134 - 147.
4Gruber A,Bjorkholm M,Brinch L,et at. A phase I/ll study of the MDR modulator Valspodar( PSC833 ) combined with daunorubicin and cytarabine in patients withrelapsed and primary refi'actory acute myeloid leukemia[ J]. Leuk Res ,2003,27:323 - 328.
5Cruz F, Wolf A. Effects of the novel cyclosporine derivative PSC833 on glucose metabolism in rat primary cultures of neuronaland filial cells[J]. Biochem Phannacol,2001,62( 1 ) :129.
7Jin J ,Wang FP,Wei H,Liu G. Reversal of muhidrug resistance of cancer through inhibition of P, glycoprotein by 5 - bromotctran- drine[ J]. Cancer Chemother Phannacol,2008,55 (2) :179.
8Ghetie MA, Marches R, Kufert S, Vitetta ES. An anti - CD19 anti- body inhibits the interaction between P - glycoprotein( P - gp) and CD19, causes P - gp to translocate out of lipid rafts,and chemosensitizes a multidrug - resistant ( MDR ) lymphoma cell line [ J ]. Blood ,2004,104( 1 ) :178.
9Yuko H, Aftra F, Yves P, et al Differential cytotoxicity of clinically important camptothecin derivatives in P - glyeoprotein overexpressing cell lines [ J ]. Cancer Chemother Phamnaeol, 1997,40 ( 5 ) : 433.
10Nokihara H, Nishioka Y,Yano S,et al. Monocyte chemoattractant protein - 1 gene modification of multi - drug resistant human lung cancer enhances antimetastatic effect of therapy with anti " P - glycoprotein antibody in SCID mice[ J]. Cancer, 1999,80(5) :773.
1Takara K, Sakaeda T,Okumura K. An update on over coming MDRl-mediated multidrug resistance in cancer chemotherapy [J]. Curt Pharm Des,2006,12(3):273- 286.
2Hai-ya Huang, Jiang-long Niu, Li-ming Zhao, et al. Reversal effeet of 2', 4'-dihydroxy-6'-methoxy 3' , 5'- dimethylchalcone on multi drug resistance in resistant human hepatocellular carcinoma cell Line BEL-7402/5- FU[J]. Phytomedicine, 2011,18 : 1086-1092.
3Tomris Ozben. Mechanisms and strategies to overcome multiple drug resistance in cancer[J]. FEBS Lett, 2006,580 : 2903-2909.
4Viera Bohacova, Zdena Sulova, Ima Dovinova, et al. L1210 cells cultivated under the selection pressure of doxorubicin or vincristine express common mechanisms of multidrug resistance based on the overexpression of P-glycoprotein [J]. Toxicol in Vitro, 2006, 20 : 1560- 1568.
5Tsuruo T, Naito M, Tomida A. Molecular targeting therapy of caner:drug resistance, apoptosis and survival signal [J]. Cancer Sci,2003,94(1) :15-21.
6M Hennessy,J P Spiers. A primer on the mechanics of P-glycoprotein the multidrug transporter[J]. Pharma- col Res,2007,55(1) :1-15.
7Kaspar P Locher. Structure and mechanism of ATP- binding cassette transporters[J]. Phil Trans R Soe B, 2009,364 : 239-245.
8Till Krech, Elisa Scheuerer, Robert Geffers, et al. AB- CB1/MDR1 contributes to the anticancer drug-resistant phenotype of IPH-926 human lobular breast cancer cells[J]. Cancer Lett,2012,315(2) :153-160.
9McDevitt C A, Callaghan R. How can we best use structural information on P-glycoprotein to design in- hibitors? [J], Pharmacol & Therapeut, 2007, 113: 429-441.
10Francisco Munoz Martinez, Carolina P Reyes, Antonio L Perez-Lomas, et al. Insights into the molecular mechanism of action of Celastraceae sesquiterpenes as specific,nowtransported inhibitors of human P-glyco- protein[J]. Biochim et Biophys Acta, 2006, 1758: 98- 110.
